C&L: Elkan Gamzu takes lead at Pharmos

Elkan Gamzu, Ph.D., has been appointed CEO of Pharmos, effective March 31. He will succeed Haim Aviv, Ph.D., who will be retiring on that date. Dr. Aviv will continue as chairman of the board.

Jack Castello, chairman of the board, president and CEO of XOMA, announced his plans to retire.

Wyeth Pharmaceuticals has appointed Geno Germano, 46, to president--U.S. and general manager, Wyeth Pharmaceuticals.

Taconic Farms has promoted Todd F. Little to president, succeeding Samuel P. Phelan. Phelan will now be responsible for Taconic's long-term strategic planning, executive development and enterprise diversification as Taconic's new CEO.

Ipsen named Stephane Thiroloix as executive vice-president, corporate development and member of Ipsen's executive committee.

Epiphany Biosciences has hired renowned virologist Michael Houghton as its first chief scientific officer.

Vaxon-Biotech has named Nadege Le Roux, MSc, PhD, to the position of director, drug development to support development phase.

VistaGen Therapeutics has named Matthew W. Kalnik, Ph.D., as executive vice president, head of business development.

NovaDel Pharma has named Deni M. Zodda, Ph.D., to the position of senior vice president and chief business officer. In addition, NovaDel announced the promotion of Frank Blondino, Ph.D., to the position of executive director, formulation and process development.

Artisan Pharma has completed hiring the senior management team of its clinical, regulatory and quality compliance group, with the addition of David Gelmont, M.D., as chief medical officer, Robin Wallace, B.S.N., as director of clinical operations and Nita U. Patel, Ph.D., as senior vice president, regulatory affairs and quality compliance.

John M. Gregory, RPH founder and former CEO of King Pharmaceuticals, has agreed to join the Stellar Pharmaceuticals' board as a new director.

The Perrigo Company has named Ben-Zion Zilberfarb as a new director of the company.

Pfizer said that Constance J. Horner, a member of the company's Board of Directors since 1993, has been elected lead director effective February 23. She succeeds Dr. Stanley O. Ikenberry, who announced plans to retire from the board effective March 22, 2007 in accordance with Pfizer's mandatory retirement age.

Caden Biosciences has named William Clarke, 55, to its board of directors.

Lexicon Genetics has elected Kathleen Wiltsey to its board of directors.

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.